Skip to main content

Table 2 Clinical characteristics of patients

From: Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1

Parameters Group1a
(n = 57)
Group2b
(n = 221)
Group3c
(n = 58)
Group4d
(n = 107)
F P
Age (mean ± SD) 60.67 ± 12.01 57.12 ± 9.31 57.07 ± 11.12 55.48 ± 9.62 3.342 0.019
Sex      2.315 0.075
 Male 52 194 44 91   
 Female 5 27 14 16   
PVTTe      0.585 0.625
 Yes 11 44 16 23   
 No 46 177 42 84   
BCLCf 0.027 0.994
 A 10 27 8 15   
 B 32 147 34 68   
 C 15 47 16 24   
Child–Pugh      3.150 0.025
 A 22 41 20 33   
 B 35 179 38 74   
 C 0 1 0 0   
Milan criteria      1.101 0.348
 Yes 14 79 20 41   
 No 43 142 38 66   
Total tumor diameter (mm) 2.740 0.043
  < 30 5 43 8 19   
 30–50 10 57 14 32   
  > 50 42 121 36 56   
Number of lesions 3.230 0.22
 1 50 161 50 87   
 2 1 12 2 6   
  ≥ 3 6 48 6 14   
  1. aGroup 1: normal-weight patients without HBV
  2. bGroup 2: normal-weight patients combined HBV
  3. cGroup 3: overweight patients without HBV
  4. dGroup 4: overweight patients combined HBV
  5. ePVTT Portal vein tumor thrombus
  6. fBCLC Barcelona Clinic Liver Cancer